Phase 3 Pneumococcal Vaccine Study for Children & Adolescents at High Risk (STRIDE-13)
Overview
STRIDE-13 is a pneumococcal vaccine research trial for children and adolescents with chronic disease (or chronic medical conditions). The purpose of the STRIDE-13 trial is to test an investigational trial vaccine that may help protect against pneumococcal disease.
Pneumococcal disease is an illness caused by certain germs (bacteria) called Streptococcus pneumoniae. These germs can cause serious infections in the ears, nose, lungs, blood, or brain. These infections can occur more frequently or be worse in children with chronic disease.
Participant Commitment
The study lasts six months. There are two in-person visits at our clinic in Halifax, NS on Day 1 and Day 30, and 3 phone calls (Day 7, Day 90, Day 180). Participants are asked to complete daily self-reports of symptoms for the first five days, and then report any adverse effects (side effects) for the first 30 days.
Eligibility
Your child may qualify to take part in this trial if they are aged 2 to 17 years old and:
Is being treated for one of these conditions:
- Diabetes
- Chronic liver disease
- Chronic lung disease
- Chronic heart disease
- Chronic kidney disease
Has completed the recommended childhood pneumococcal conjugate vaccine regimen prior to 2 years of age.
Other detailed eligibility will be confirmed by study staff.
